This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DaVita's (DVA) Collaboration to Aid in Kidney Care Needs
by Zacks Equity Research
DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.
PacBio (PACB) to Leverage Google's Deep Learning Technologies
by Zacks Equity Research
PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
by Zacks Equity Research
PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.
Company News for Jan 12, 2022
by Zacks Equity Research
Companies in The News Are: ACCD,PACB,BIG,ILMN
PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability
by Zacks Equity Research
PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.
PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada
by Zacks Equity Research
PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.
PacBio's (PACB) New Surveillance Kit Successful Against Omicron
by Zacks Equity Research
PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research
by Zacks Equity Research
PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.
PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis
by Zacks Equity Research
PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.
PacBio's (PACB) New Solution to Boost Public Health Protection
by Zacks Equity Research
PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.
PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -9.52% and 5.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pacific Biosciences of California (PACB) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division
PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research
by Zacks Equity Research
PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.
PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.
Pacific Biosciences (PACB) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -5.00% and 0.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pacific Biosciences of California (PACB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH